Conversely, SLAMF1 and FGF‐5, whose levels were elevated in LLV, are implicated in immune regulation and malignancy progression, possibly contributing to lower ICI efficacy in HCC [18, 19, 20, 21, 22, 23, 24]. The gene discussed is FGF5; the disease is hepatocellular carcinoma.